Pharmaceuticals
Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep
Preclinical study shows 1.5- to 2-hour increase in total sleep time as Company
advances toward clinical development and attracts Chris Brearley, M.D., as
Chief Medical Officer
INDIANAPOLIS, Oct. 23, 2026 /PRNewswire/ -- Carnyx Therapeutics Ltd.
2026-10-23 08:30
382
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building on positive Phase III clinical results in China from Ascletis - Pivotal trial designed to enroll approxima...
2026-10-23 08:10
556
Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration
Building on more than five decades in Hong Kong, Johnson & Johnson is committed to advancing better health through science, innovation and collaboration for patients and communities in Hong Kong. The partnership will help strengthen clinical research, develop future healthcare talent and su...
2026-10-22 23:52
2893
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
* GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. * Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties. FLORENCE, It...
2026-10-22 22:30
2662
ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow
The ZEISS CT LUCIA 621P monofocal intraocular lens (IOL) is added to the ZEISS Cataract Workflow in the Japanese market, supporting good visual outcomes for patients. JENA, Germany and TOKYO, Oct. 22, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today the commercial availability of th...
2026-10-22 21:00
959
Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa
SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtypes of Epidermolysis Bullosa MOUNT PLEASANT, S.C., Oct. 22, 2026 /PRNewswire/ -- Paradigm Therapeutics, Inc., a clinical-stage biopharmace...
2026-10-22 20:00
1336
Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization
Indegene is recognized for combining domain-led AI, knowledge orchestration,
and integrated execution to transform pharmaceutical commercialization
workflows.
SAN ANTONIO, Oct. 22, 2026 /PRNewswire/ -- Frost & Sullivan
2026-10-22 13:30
1532
Taimei Technology and GreenLight Clinical Expand Strategic Partnership at AusBiotech 2026 to Pioneer AI-Native Trial Execution Across Asia-Pacific
GOLD COAST, Australia, Oct. 22, 2026 /PRNewswire/ -- Taimei Technology, a global provider of AI-powered clinical development platforms, and GreenLight Clinical (GLC), a physician-led contract research organization (CRO), today announced an expanded strategic partnership at AusBiotech 2026. Evolvi...
2026-10-22 08:00
2488
Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids
DUBLIN, Oct. 22, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced today that its THERAKOS™ CELLEX™ Photopheresis System has received certification under the EU MDR for an ...
2026-10-22 02:01
2522
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
* The study evaluates patients with liver cancer at high risk of recurrence following surgical resection * Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, Oct. 21, 2026 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focus...
2026-10-21 21:10
4060
Axtria Wins 2026 Minsky Award for Excellence in AI for the Third Consecutive Year
AI-powered Next Best Action solution generated more than $180 million in
incremental revenue for a brand for a global pharmaceutical leader
BERKELEY HEIGHTS, N.J., Oct. 21, 2026 /PRNewswire/ -- Axtria Inc.
2026-10-21 20:15
1410
ESTEVE CDMO expands its presence in Asia with a major investment and new manufacturing site in China
* After more than two decades in China, ESTEVE CDMO marks a new chapter in its commitment to the country and the region. * With more than $80 million invested, the new facility brings a new generation of manufacturing capabilities, with 250 m³ of reaction volume and potential capacity of more...
2026-10-21 18:41
2235
Chen Qiyu: Building on "Affordability & Reliability", Fosun Expands the Global Reach of Chinese Innovative Drugs
HONG KONG, Oct. 21, 2026 /PRNewswire/ -- On 20 October, the Sustainability Global Leaders Conference 2026 was held in Shanghai. The Conference, themed "Building a Resilient Future Together: Global Governance, Innovation-Driven Growth, and Industrial Upgrading", brought together more than 300 gues...
2026-10-21 16:52
1939
CSL appoints Deborah Waterhouse as CEO & Managing Director
MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 February 2027. The appointment was made following an extensive g...
2026-10-21 15:56
2429
Telix Reports Third Quarter 2026 Financial Performance
MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026). Q3 2026 Highlights[1] * Group reven...
2026-10-21 06:08
3034
Patronus Biotech Receives Ethical Approval to Begin First-in-Human Phase 1 Trial of Three Multi-Stage Vaccines Against Malaria in Australia
Bellberry Limited Research Ethics Committee approves first-in-human study in Australia of Patronus Biotech's novel multi-stage virus-like-particle (VLP)-based malaria vaccine candidates targeting Plasmodium falciparum and Plasmodium vivax GUANGZHOU, China, Oct. 20, 2026 /PRNewswire/ -- Patronus ...
2026-10-20 20:40
1520
New Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVD
A Collaboration Leads to Molecularbiological Innovation MUNICH, Oct. 20, 2026 /PRNewswire/ -- AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, "eazySNP" combines the highly specialized molecular technologies LAM...
2026-10-20 14:10
955
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
- Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations. - ASC36o, a once-weekly oral amylin receptor peptide agonist, is the most advanced drug candidate of Ascletis' once-weekly oral peptide p...
2026-10-20 08:10
3331
Frost & Sullivan awards WuXi AppTec with 2026 Global Company of the Year Recognition for CRDMO Leadership
Integrated capabilities, global capacity, and customer-centric innovation
strengthen WuXi AppTec's position in the evolving contract research,
development, and manufacturing (CRDMO) landscape.
SAN ANTONIO, Oct. 20, 2026 /PRNewswire/ -- Frost & Sullivan
2026-10-20 08:00
2154
OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors
— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies — Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in China ROCKVILLE, Md. , Oct. 19, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage biopharmaceutical co...
2026-10-19 19:16
1799
Week's Top Stories
Most Reposted
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 275 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 270 media titles]
2026-10-22 11:55Carro Establishes Inaugural SGD450 Million Asset-Backed Securitisation Warehouse Facility
[Picked up by 267 media titles]
2026-10-22 11:00Ready Server Launches ReadyServer LLM API, Giving Every VPS Customer Private AI Inference at No Extra Cost
[Picked up by 265 media titles]
2026-10-20 14:10Most Read
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
12533
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
2026-10-19 13:18
11921
FinDev Canada provides a USD 60 million loan to Muangthai Capital to advance gender equality and private sector investment in Thailand
2026-10-17 00:54
11841
BUUU Group Limited Announces 10-for-1 Forward Share Split
2026-10-17 04:30
11174